Baxter Launches At-Risk Generic During Appeal

Law360, New York (January 2, 2006, 12:00 AM EST) -- Baxter Healthcare Corp. has ignored an appeal by rival Abbott Laboratories to launch at risk a generic version of Abbot’s popular inhaled anesthetic Ultane in the United States, Europe and Japan in 2006.

A favorable district court ruling in late September 2005 gave Baxter the green light to begin marketing sevoflurane, the active ingredient in Ultane. But Abbott appealed the decision, prompting some analysts to suspect the launch would be delayed.

Abbott sued Baxter in March 2001, when the generic maker filed an Abbreviated New Drug...
To view the full article, register now.